More particularly they are selective agonists at Somatostatin sst.sub.2 receptors, as determined in radioligand binding and second messenger studies [see for example K.Kaupmann et al., FEBS LETTERS 1993, 331: 53 59].The compounds of the invention are therefore indicated for use in anxiety, depression, schizophrenia, neurodegenerative diseases such as dementia, epilepsy, endocrinological disorders